Cochrane Review Finds Anti-Amyloid Alzheimer's Drugs Lack Clinically Meaningful Effect, Sparking Debate on April 17, 2026 Alzheimer 's disease Amyloid beta-Peptides anti-amyloid drugs Brain hemorrhage Clinical Trials Cochrane review Donanemab Lecanemab Neuregulins +
Korsana Biosciences Goes Public Through Reverse Merger with Cyclerion Therapeutics on April 02, 2026 Alzheimer 's disease Amyloid beta-Peptides Blood - brain barrier anatomy Cyclerion Therapeutics Korsana Biosciences KRSA-028 Paragon Therapeutics reverse merger +
Korsana Biosciences Launches with $175M to Develop Brain-Penetrant Alzheimer's Antibody on February 19, 2026 Alzheimer 's disease Amyloid beta-Peptides anti-amyloid antibody Blood - brain barrier anatomy Korsana Biosciences KRSA-028 Paragon Therapeutics THETA platform +